Bivalent second booster dose of the COVID-19 vaccine: Eligible populations' reasons for receiving in Italy

Hum Vaccin Immunother. 2023 Dec 31;19(1):2188856. doi: 10.1080/21645515.2023.2188856. Epub 2023 Mar 29.

Abstract

The Italian Ministry of Health recommended the administration of the bivalent second booster dose of the new available mRNA COVID-19 vaccine for subjects aged 60 y and over, aged 12 y and over with high frailty motivated by concomitant/preexisting conditions, and health-care workers. The purposes of this cross-sectional survey were to investigate the reasons for receiving the bivalent second booster dose of the COVID-19 vaccine and associated influencing factors among the eligible population attending two immunization centers randomly selected in the city of Naples, Italy. A total of 535 subjects participated. Only 17.5% revealed high concern about the possibility of acquiring the COVID-19 disease. Those younger, those who had at least one chronic medical condition, and those who had a higher perceived seriousness of the COVID-19 disease were more likely to be very concerned. Having a higher belief of the vaccine's safety and usefulness were significant positive predictors of the respondents' belief of the efficacy of the bivalent second booster dose. The two most common reasons reported for receiving the bivalent second booster dose included the protection for themselves and for their cohabitants. Those younger and those who had a higher perception of the vaccine's usefulness in preventing SARS-CoV-2 infection were more likely to receive the bivalent second booster dose for the protection of their cohabitants. Health-care organizations and health-care professionals can use these findings in their efforts to design educational and communication interventions to accelerate the uptake of this vaccine for reducing the frequency of this disease.

Keywords: Bivalent booster dose; COVID-19; Italy; survey; vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19 Vaccines*
  • COVID-19* / prevention & control
  • Cross-Sectional Studies
  • Humans
  • Italy / epidemiology
  • SARS-CoV-2

Substances

  • COVID-19 Vaccines

Grants and funding

This work was supported by a grant of the Regione Campania (DGR n.140/2020 Urgent measures regarding the containment and management of the epidemiological emergency from COVID-19, POR Campania FESR 2014-2020, Asse Prioritario 1 “Ricerca e Innovazione”).